Hengdi Pharmaceutical: It is expected that the net profit attributable to the parent company will decrease by 66.14% to 57.40% compared to 2025.

Hengdi Pharmaceuticals announced on January 13 that it is expected to have a net profit attributable to shareholders of 31-39 million yuan in 2025, a year-on-year decrease of 66.14%-57.40%. The change in performance is mainly due to intensified market competition for its main product ibuprofen bulk drug and some specialty bulk drug products, leading to a decrease in gross profit margin; and a reduction in interest income from cash management due to a decrease in interest rates.